# US 2024/0425542 A1 · Cyclic deoxyribonucleotide compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0425542 A1
- Document ID: US20240425542A1
- Status: Published application
- Kind: A1
- Application number: 18/826,713
- Filed: 2024-09-06
- Published: 2024-12-26
- Earliest claimed: 2019-07-17
- Assignees: Nucorion Pharmaceuticals, Inc.
- Applicants: Nucorion Pharmaceuticals, Inc.
- Inventors: Lin Zhi
- Web page: https://patentgrep.com/patent/US20240425542A1

## CPC

- C07H 19/10: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 35/00: Antineoplastic agents
- C07H 19/11: containing cyclic phosphate
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are 5-fluorouracil derived cyclic deoxyribonucleotide compounds, their preparation and their uses, such as treating liver diseases or various types of cancer.

## Claims

### Claim 1

A method of treatment, comprising:
conducting a medical procedure; and
administering a compound of Formula I, Ia, or II:
or a stereoisomer or a pharmaceutically acceptable salt thereof,
wherein:
R1 is selected from the group consisting of H, halo, C1-C10 alkyl, —O—C1-6 alkyl, —O-carboxy, —OCH2OR9, —CH(OR9)2, —C-carboxy, —C-amido, —CH2OCH2OR9,
and —CH2O-carboxy;
each R2 is independently H, halo, or a C1-C10 alkyl;
R3 is selected from the group consisting of —O-carboxy, —OCH2OR9, —CH(OR9)2, —C-carboxy, —C-amido, —CH2OCH2OR9,
—CH2O-carboxy, C1-C10 alkyl, and C3-C10 cycloalkyl;
R4 is an optionally substituted C1-C10 alkyl;
each R5 and R6 are independently H or a C1-C10 alkyl; or alternatively, an R5 and R6 attached to the same carbon atom may be taken together with the atom to which they are attached form a C3-C10 cycloalkyl;
each R7 and R8 are independently H or a C1-C10 alkyl; or alternatively, an R7 and R8 attached to the same carbon atom may be taken together with the atom to which they are attached form a C3-C10 cycloalkyl; and
R9 is an optionally substituted C1-C10 alkyl;
provided that the compound is not selected from:

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound is a compound of Formula (1) or (II):
or a stercoisomer or a pharmaceutically acceptable salt thereof, wherein:
R1 is selected from the group consisting of H, F, C1-C10 alkyl, —OMe, —OEt, —O-carboxy, —OCH2OR9, —CH(OR9)2, —C-carboxy, —C-amido, —CH2OCH2OR9,
and —CH2O-carboxy; and
R2 is H, F, or a C1-C10 alkyl.

### Claim 3 (depends on 1)

The method of claim 1, wherein R1 is H; and R2 is H or F.

### Claim 4 (depends on 1)

The method of claim 1, wherein R1 is selected from the group consisting of —OMe, —OEt, —O-carboxy, —OCH2OR9, —CH(OR9)2, —C-carboxy, —C-amido, —CH2OCH2OR9, and-CH2O-carboxy.

### Claim 5 (depends on 1)

The method of claim 1, wherein R1 is F or —C-carboxy.

### Claim 6 (depends on 1)

The method of claim 1, wherein R2 is H or F.

### Claim 7 (depends on 1)

The method of claim 1, wherein R3 is selected from the group consisting of —O-carboxy, —OCH2OR9, —CH(OR9)2, —C-carboxy, —C-amido, —CH2OCH2OR9,
and —CH2O-carboxy.

### Claim 8 (depends on 1)

The method of claim 1, wherein R3 is C1-C10 alkyl or C3-C10 cycloalkyl.

### Claim 9 (depends on 1)

The method of claim 1, wherein the compound has the structure of Formula Ia:
or a stereoisomer or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 9)

The method of claim 9, wherein R4 is C1-C10 alkyl.

### Claim 11 (depends on 9)

The method of claim 9, wherein each R2 is H.

### Claim 12 (depends on 1)

The method of claim 1, wherein the compound is selected from the group consisting of:
or a stereoisomer or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

The method of claim 1, wherein the medical procedure is trans-arterial chemoembolization.

### Claim 14

A method of treating a disease, disorder or condition comprising administering an effective amount of a compound of Formula I, Ia, or II:
or a stereoisomer or a pharmaceutically acceptable salt thereof,
wherein:
R1 is selected from the group consisting of H, halo, C1-C10 alkyl, —O-C1-6 alkyl, —O-carboxy, —OCH2OR9, —CH(OR9)2, —C-carboxy, —C-amido, —CH2OCH2OR9,
and-CH2O-carboxy;
each R2 is independently H, halo, or a C1-C10 alkyl;
R3 is selected from the group consisting of —O-carboxy, —OCH2OR9, —CH(OR9)2, —C-carboxy, —C-amido, —CH2OCH2OR9,
—CH2O-carboxy, C1-C10 alkyl, and C3-C10 cycloalkyl;
R4 is an optionally substituted C1-C10 alkyl;
each R5 and R6 are independently H or a C1-C10 alkyl; or alternatively, an R5 and R6 attached to the same carbon atom may be taken together with the atom to which they are attached form a C3-C10 cycloalkyl;
each R7 and R8 are independently H or a C1-C10 alkyl; or alternatively, an R7 and R8 attached to the same carbon atom may be taken together with the atom to which they are attached form a C3-C10 cycloalkyl; and
R9 is an optionally substituted C1-C10 alkyl; provided that the compound is not selected from:
to a subject in need thereof wherein the disease, disorder, or condition is cancer in the liver.
